Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients

Transplantation

Volumn 80, Issue 11, 2005, Pages 1546-1549

  Tricot, Leila ^a   Lebbé, Céleste ^b   Pillebout, Evangéline ^b   Martinez, Frank ^a   Legendre, Christophe ^a   Thervet, Eric ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Alopecia; Kidney pancreas transplantation; Tacrolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; MINOXIDIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGE DISTRIBUTION; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RECIPIENT; RISK FACTOR; SEX DIFFERENCE;

ALOPECIA; ANTILYMPHOCYTE SERUM; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; TACROLIMUS;

EID: 29344474207     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000181195.67084.94     Document Type: Article

References (13)

1. Wolfe RA, Ashby VE, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
2. Overbeck I, Bartels M, Decker O, et al. Changes in Quality of Life After Renal Transplantation. Transplant Proc 2005; 37: 1618-1621.
3. Shield CF III, McGrath MM, Goss TF. Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression. FK506 Kidney Transplant Study Group. Transplantation 1997; 64: 1738-1743.
4. Peters TG, Spinola KN, West JC, et al. Differences in patient and transplant professional perceptions of immunosuppression-induced cosmetic side effects. Transplantation 2004; 78: 537-543.
5. Kuypers DR, Malaise J, Claes K, et al. Secondary effects of immunosuppressive drugs after simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005; 20: ii33-ii39.
6. Shapiro R, Jordan ML, Scantlebury VP, et al. Alopecia as a consequence of tacrolimus therapy. Transplantation 1998; 65: 1284.
7. Talbot D, Rix D, Abusin K, et al. Alopecia as a consequence of tacrolimus therapy in renal transplantation? Transplantation 1997; 64: 1631-1632.
8. Kim HC, Hwang EA, Han SY, et al. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. Transplant Proc 2004; 36: 2082-2083.
9. Hequet O, Vocanson M, Saint-Mezard P, et al. CD4+ T cells prevent skin autoimmunity during chronic autologous graft-versus-host-disease. Am J Transplant 2004; 4: 872-878.
10. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000; 42: 349-566.
11. Oliver RF, Lowe JG. Oral cyclosporin A restores hair growth in the DEBR rat model for alopecia areata. Clin Exp Dermatol 1995; 20: 127-131.
12. Shapiro R, Fung JJ, Jain AB, et al. The side effects of FK 506 in humans. Transplant Proc 1990; 22: 35-36.
13. Gebhart W, Schmidt JB, Schemper M, et al. Cyclosporin-A-induced hair growth in human renal allograft recipients and alopecia areata. Arch Dermatol Res 1986; 278: 238-240.